Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1989 1
1990 1
1991 1
1992 2
1993 1
1994 1
1996 2
1997 1
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

10 results
Results by year
Filters applied: . Clear all
Page 1
The RAD52 epistasis group in mammalian double strand break repair.
Petrini JH, Bressan DA, Yao MS. Petrini JH, et al. Semin Immunol. 1997 Jun;9(3):181-8. doi: 10.1006/smim.1997.0067. Semin Immunol. 1997. PMID: 9200329 Review.
Concentration and timing dependence of lethality enhancement between topotecan, a topoisomerase I inhibitor, and ionizing radiation.
Lamond JP, Wang M, Kinsella TJ, Boothman DA. Lamond JP, et al. Int J Radiat Oncol Biol Phys. 1996 Sep 1;36(2):361-8. doi: 10.1016/s0360-3016(96)00328-8. Int J Radiat Oncol Biol Phys. 1996. PMID: 8892461
Evidence of an absorption phase after short intravenous suramin infusions.
Hutson PR, Tutsch K, Spriggs D, Christian M, Rago R, Mutch R, Wilding G. Hutson PR, et al. Cancer Chemother Pharmacol. 1993;31(6):495-9. doi: 10.1007/BF00685042. Cancer Chemother Pharmacol. 1993. PMID: 8453691 Clinical Trial.
4-Hydroxytamoxifen, an active metabolite of tamoxifen, does not alter the radiation sensitivity of MCF-7 breast carcinoma cells irradiated in vitro.
Sarkaria JN, Miller EM, Parker CJ, Jordan VC, Mulcahy RT. Sarkaria JN, et al. Breast Cancer Res Treat. 1994;30(2):159-65. doi: 10.1007/BF00666060. Breast Cancer Res Treat. 1994. PMID: 7949215
Increase in gamma-glutamylcysteine synthetase activity and steady-state messenger RNA levels in melphalan-resistant DU-145 human prostate carcinoma cells expressing elevated glutathione levels.
Bailey HH, Gipp JJ, Ripple M, Wilding G, Mulcahy RT. Bailey HH, et al. Cancer Res. 1992 Sep 15;52(18):5115-8. Cancer Res. 1992. PMID: 1355406 Free article.
Phase I evaluation of 773U82-HCl in a two-hour infusion repeated daily for three days.
Bailey H, Kohler P, Tuttle R, Carbone PP, Hohneker JA, Clendeninn NJ, Wilding G. Bailey H, et al. Invest New Drugs. 1992 Nov;10(4):279-87. doi: 10.1007/BF00944182. Invest New Drugs. 1992. PMID: 1487401 Clinical Trial.